Concepedia

Musa Yılmaz

MY

Statistics

Publications

128

Citations

6.9K

H-Index

45

Active since

2011

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of California, Irvine

The University of Texas Health Science Center at Houston

Albert Einstein College of Medicine

Musa Yılmaz is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and chemotherapy.

Publications per year

2011–2025

128

Publications

128

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Nitin Jain, Michael J. Keating, Philip A. Thompson et al. · New England Journal of Medicine · 2019 · 504 citations · Full text

Medicine, Hematology, Oncology +17

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Timothy A. Yap, Naval Daver, Mikhila Mahendra et al. · Nature Medicine · 2023 · 377 citations

Medicine, Oncology, Pharmacology +14

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Courtney D. DiNardo, Curtis A. Lachowiez, Koichi Takahashi et al. · Journal of Clinical Oncology · 2021 · 334 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch et al. · The Lancet Haematology · 2020 · 331 citations · Full text

Medicine, Hematology, Oncology +16

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short et al. · The Lancet Oncology · 2018 · 241 citations · Full text

Medicine, Hematology, Oncology +13

1–5 of 128